sameAs
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phaseSequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia.A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations.Chronic myelogenous leukemia in chronic phase.Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatinChronic myelogenous leukemia: elements of conventional chemotherapy and an overview of autografting in the treatment of the chronic phase.Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisHigher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature.Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.Determinants of prognosis in late chronic-phase chronic myelogenous leukemia.BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system.The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients.Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone mQuantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China.Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.Case of chronic-phase chronic myelogenous leukemia with an abdominal hematopoietic tumor of leukemic clone origin.Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients.Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib.Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia.Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.The simultaneous occurrence of variant hairy cell leukemia and chronic-phase chronic myelogenous leukemia. A case report.Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
P921
Q26749343-E50D695C-BB40-4B1C-A19A-B2568B0C73F3Q33329122-9F526433-A195-4351-99DD-59D04D76FBA2Q33457381-B990BF1D-EEB7-492F-8882-FA9DE44DD61AQ34339134-68BDDD07-7F99-4F68-80E5-D7CB61D793F7Q34678295-33458819-9AE5-475F-86DE-4E574B09A2EEQ35034528-7FE76271-7A05-4F14-9B8B-4EC1B507EC6FQ35166751-3D4B10CF-618E-4E5E-816F-05903EC61B1FQ36624496-ACD84C0E-DA2E-44BB-9866-1EE025D77D2BQ37212678-1EAAB67C-09CD-4C71-9883-F4033177F616Q37505017-9B0CCEFB-F917-4C2F-9A39-93DE00BD6322Q38125185-B8D2785A-D3EC-4588-AB18-B17D7F4FBF6DQ38281465-4991DA49-1458-4A1A-9502-1DF500E4B3DAQ38404422-784952DE-C8A3-4FB2-9967-21E2F73880B5Q38587961-1341E7B0-E6AA-40C3-A830-A05C1227A075Q39038195-4152ABAB-D3D0-4C67-93FB-65D376E73C50Q40832135-68F46C84-93F1-4431-9C88-2E977F35CEB8Q42694242-8CAD008F-3113-4DE1-9C84-90E1147B4B88Q42844339-D33F00E1-8C4C-4434-989F-ABC17ED52ED6Q42923860-5E74782B-9728-4FA6-A4D4-F06F939D8AC6Q43600764-B6698E75-8D42-4DE4-BBC3-2604E3D3270EQ43947310-1DE638DD-8542-4B06-9DEB-001AA6690377Q43957360-1E3E30B9-FC01-4EC0-974B-80939B329888Q44285235-F7EB9B3D-0E71-4609-8B76-09069CA402C4Q44493549-53B578C2-903E-42A8-9809-3D03D4186CA6Q44679459-C7C68E1E-652F-4093-B2B6-F16A7C533E1FQ44718887-ABF0D955-2C3D-4879-8491-A06279844398Q44937081-AA9D50E4-E2D9-4BD1-9AB7-384021EEEF82Q45076580-D24BDCAD-4D9D-4212-95A9-066E30B84333Q45760321-9DB1D118-65E7-4C6E-9D1E-5195CF4A0B62Q46428514-EDCE8FA2-65CF-46E0-BACB-1F74DE33E5A8Q46560906-DC476642-CC0A-431C-AF45-9D3D5322D91AQ46788332-F145CAE1-07C0-4038-A1F5-EE869E5887DCQ46818304-273C675C-2B8B-41CE-93A5-08ED6889DE12Q51309944-19C55896-577C-4DF7-BCCD-502215057DD7Q53294924-8A213646-1C56-4429-9882-70C8607CBB76Q53350066-FD90F3D1-85DA-40A3-AA24-CAFFB0D8C5A4Q53490866-28D8BEA0-D4C8-45AF-8709-A25C4B2474FFQ54144461-C70457BE-B086-40B0-922B-688C5A413CBEQ54175120-BDAB0B4C-FBFB-462E-822C-843836972D05Q54228292-EFF90945-8211-4275-BF3A-3A95EE0F19E7
P921
description
initial phase of chronic myelo ...... riod lasting from 4 to 7 years
@en
name
Chronic phase chronic myelogenous leukemia
@en
leucémie myéloïde en phase chronique
@fr
type
label
Chronic phase chronic myelogenous leukemia
@en
leucémie myéloïde en phase chronique
@fr
altLabel
chronic phase myeloid leukemia
@en
prefLabel
Chronic phase chronic myelogenous leukemia
@en
leucémie myéloïde en phase chronique
@fr
P486
P6366
P1995
P31
P486
P6366
2779069263
P672
C04.557.337.539.250.400